<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03613233</url>
  </required_header>
  <id_info>
    <org_study_id>0000000417</org_study_id>
    <nct_id>NCT03613233</nct_id>
  </id_info>
  <brief_title>QoL Assessment in Traditional Glaucoma Surgery and MIGS.</brief_title>
  <official_title>Quality of Life Assessment in Traditional and Microinvasive Glaucoma Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Military Institute of Medicine, Poland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Military Institute of Medicine, Poland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Quality of Life assessment before and after various glaucoma surgery (traditional and
      microinvasive (MIGS)).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients qualified for glaucoma surgical procedure fill in QoL questionnaire (NEI VFQ 25) at
      baseline (pre-operatively) and 3 months after glaucoma surgery. Additional data will be
      collected such as demographic data and medical data, visual acuity, intraocular pressure,
      number of glaucoma medications, stage of glaucoma based on visual field assessment, medical
      ophthalmic history, intra and postoperative complications, postoperative interventions.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NEI VFQ 25 quality of life score change</measure>
    <time_frame>baseline (0-30 days; pre-operative) and three months after surgery</time_frame>
    <description>NEI VFQ 25 baseline and 3 months after surgery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>traditional glaucoma surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>glaucoma procedures such as trabeculectomy, iridencleisis, non - penetrating deep sclerectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>microinvasive glaucoma surgery (MIGS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>glaucoma procedures such as : canaloplasty (traditional, ABiC, modified), iStent, XEN, Cypass,Hydrus- and with any other microinvasive IOP reducing device</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Glaucoma surgery</intervention_name>
    <description>phacoemulsification</description>
    <arm_group_label>microinvasive glaucoma surgery (MIGS)</arm_group_label>
    <arm_group_label>traditional glaucoma surgery</arm_group_label>
    <other_name>cataract surgery when required</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        patients qualified for glaucoma surgery in Military Institute of Medicine - based on
        following Inclusion Criteria:

          -  all glaucoma types with characteristic glaucoma changes (biomicroscopic ,visual field)
             with documented glaucoma progression

          -  patients not tolerating antiglaucoma medications,

          -  patients with poor compliance

          -  progression in visual field

        Exclusion Criteria:

          -  active inflammatory disease

          -  pregnancy

          -  mental disease or emotional instability

          -  general steroid therapy

          -  inability to fill in the questionnaire
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Byszewska, MD, PhD</last_name>
    <phone>500285890</phone>
    <phone_ext>48</phone_ext>
    <email>ania.byszewska@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marek Rękas, prof.; MD; PhD</last_name>
    <email>mrekas@wim.mil.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Military Institute of Medicine</name>
      <address>
        <city>Warsaw</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Byszewska, MD,PhD</last_name>
      <phone>500285890</phone>
      <phone_ext>48</phone_ext>
      <email>ania.byszewska@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 29, 2018</study_first_submitted>
  <study_first_submitted_qc>July 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>July 29, 2018</last_update_submitted>
  <last_update_submitted_qc>July 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Military Institute of Medicine, Poland</investigator_affiliation>
    <investigator_full_name>Marek Rekas</investigator_full_name>
    <investigator_title>płk prof. Marek RĘKAS, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>MIGS</keyword>
  <keyword>canaloplasty</keyword>
  <keyword>glaucoma</keyword>
  <keyword>glaucoma surgery</keyword>
  <keyword>glaucoma implant</keyword>
  <keyword>deep sclerectomy</keyword>
  <keyword>iridencleisis</keyword>
  <keyword>QoL</keyword>
  <keyword>quality of life</keyword>
  <keyword>NEI VFQ 25</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

